Provided by Tiger Trade Technology Pte. Ltd.

GlucoTrack, Inc.

3.14
-0.0050-0.16%
Volume:3K
Turnover:9.01K
Market Cap:2.21M
PE:-0.03
High:3.14
Open:3.04
Low:3.04
Close:3.14
52wk High:212.10
52wk Low:2.90
Shares:705.25K
Float Shares:701.36K
Volume Ratio:0.89
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-112.7747
EPS(LYR):-468.2383
ROE:-620.63%
ROA:-164.45%
PB:-1.27
PE(LYR):-0.01

Loading ...

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

GlobeNewswire
·
May 15

GlucoTrack Inc - Submits Ide Application to FDA for US Clinical Study of Implantable Cbgm Technology - SEC Filing

THOMSON REUTERS
·
May 08

Glucotrack submits IDE application to FDA for US implantable glucose monitor study

Reuters
·
May 08

GlucoTrack Announces Ide Submission for U.S. Clinical Study of Its Novel Implantable Continuous Blood Glucose Monitoring Technology

THOMSON REUTERS
·
May 08

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

GlobeNewswire
·
Apr 30

GlucoTrack announces publication of peer-reviewed article on glucose sensors

TIPRANKS
·
Apr 21

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

GlobeNewswire
·
Apr 21

GlucoTrack issues 895,000 unregistered shares in $600,000 note exchange

Reuters
·
Apr 15

GlucoTrack Q4 EPS $(3.97) Up From $(1.24 thousand) YoY

Benzinga Earnings
·
Mar 31

GlucoTrack FY25 net loss narrows to US$19.4 million; R&D expenses rise to US$9.8 million

Reuters
·
Mar 31

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

GlobeNewswire
·
Mar 31

Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?

TIPRANKS
·
Mar 27

GlucoTrack to file IDE to FDA for continuous blood glucose monitoring technology

TIPRANKS
·
Mar 27

BRIEF-Glucotrack To File Significant Ide With FDA For Us Clinical Trial In Early Q2 Based On Critical 2025 Milestones

Reuters
·
Mar 27

GlucoTrack files FDA IDE in Q2 2026; first-in-human CBGM study posts 7.7% MARD

Reuters
·
Mar 27

GlucoTrack to File Significant Ide With FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

THOMSON REUTERS
·
Mar 27